Recombinant Immunoglobulin Library Generation from Single Immune Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for antibody drug discovery are expensive and tedious, relying on the identification of antigens and the isolation and production of antibodies, which often result in a narrower treatment mechanism than the natural immune response.
Innovation Solution
A method for generating a recombinant immunoglobulin library by isolating single immune cells, amplifying and linking heavy and light chain variable domain encoding polynucleotides, and circularizing these constructs to create a library of unique recombinant immunoglobulins that can be expressed in host cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional antibody isolation and production methods are used, then antibody therapeutics can be obtained, but the process is expensive and tedious with limited treatment scope
Solution Approach 1:
The patent segments the antibody production process by isolating individual B cells and their cognate pairs (heavy and light chains) separately, then recombining them in a controlled manner. This allows systematic generation of diverse antibody variants while maintaining manufacturability through standardized molecular biology techniques.
Solution Approach 2:
The patent creates a universal platform for antibody discovery that can be applied to multiple antigens and disease indications. By establishing a standardized process for isolating, characterizing, and recombining B cell receptors, the method enables diverse therapeutic applications from a single platform technology.
2Device complexity
If limited numbers of antibodies are selected and expressed, then the discovery process remains manageable, but the treatment mechanism becomes narrower than natural immune response
Solution Approach 1:
The patent performs preliminary characterization of B cell receptors by isolating and sequencing cognate pairs from naive B cells before antigen exposure. This pre-characterization creates a baseline library that can be systematically expanded and modified to generate diverse therapeutic candidates without requiring de novo discovery for each application.
Solution Approach 2:
The patent nests multiple levels of diversity within the antibody library structure by combining variable regions from different B cell clones, creating hierarchical layers of variation. This nested approach allows manageable library construction at each level while achieving comprehensive diversity at the final product level.
3Productivity
If natural immune repertoires are utilized through high-throughput methods, then diverse antibody therapies can be generated, but advanced molecular biology techniques are required
Solution Approach 1:
The patent employs self-service mechanisms where the biological system itself provides the diversity generation. By harvesting B cell receptors directly from natural immune repertoires and using the cells' own molecular machinery for RNA extraction and cDNA synthesis, the method achieves high throughput while leveraging biological self-organization to reduce procedural complexity.
Solution Approach 2:
The patent replaces manual, step-by-step molecular biology operations with automated high-throughput workflows. By implementing robotic liquid handling, automated PCR setup, and high-throughput sequencing integration, the system substitutes mechanical manual operations with automated systems, increasing throughput while standardizing complex procedures.
Data Source
AI summary
Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.